BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26996662)

  • 1. Rajavithi-ovarian cancer predictive score (R-OPS): A new scoring system for predicting ovarian malignancy in women presenting with a pelvic mass.
    Yanaranop M; Tiyayon J; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
    Gynecol Oncol; 2016 Jun; 141(3):479-484. PubMed ID: 26996662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
    Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
    Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Accuracy and Optimal Cutoff Value of Serum HE4 to Predict Ovarian Cancer in Thai Women with Pelvic Masses.
    Yanaranop M; Tiyayon J; Nakrangsee S; Thinkhamrop B
    J Med Assoc Thai; 2016 Dec; 99(12):1263-71. PubMed ID: 29952496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.
    Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM
    Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
    Yanaranop M; Jantarateptewan N; Tiyayon J; Nakrangsee S
    Int J Gynecol Cancer; 2018 Jul; 28(6):1058-1065. PubMed ID: 29975290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
    Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
    Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
    Goff BA; Agnew K; Neradilek MB; Gray HJ; Liao JB; Urban RR
    Gynecol Oncol; 2017 Nov; 147(2):291-295. PubMed ID: 28860006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
    Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
    Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
    Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
    Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
    Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
    Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy.
    Teh BH; Yong SL; Sim WW; Lau KB; Suharjono HN
    Horm Mol Biol Clin Investig; 2018 Jul; 35(1):. PubMed ID: 30063463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses.
    Gentry-Maharaj A; Burnell M; Dilley J; Ryan A; Karpinskyj C; Gunu R; Mallett S; Deeks J; Campbell S; Jacobs I; Sundar S; Menon U
    Am J Obstet Gynecol; 2020 Jan; 222(1):56.e1-56.e17. PubMed ID: 31351062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proposal for a new scoring system to evaluate pelvic masses: Pelvic Masses Score (PMS).
    Rossi A; Braghin C; Soldano F; Isola M; Capodicasa V; Londero AP; Forzano L; Marchesoni D
    Eur J Obstet Gynecol Reprod Biol; 2011 Jul; 157(1):84-8. PubMed ID: 21440361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.
    Chen YN; Ma F; Zhang YD; Chen L; Li CY; Gong SP
    Curr Med Sci; 2020 Feb; 40(1):184-191. PubMed ID: 32166682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Sonographic Morphology Score and Tumor Markers for Detecting Postoperative Recurrent Pelvic Ovarian Carcinoma: Compared With MRI Assessment.
    Shen ZY; Shen AJ; Yang SL; Wu MF
    Ultrasound Q; 2019 Mar; 35(1):45-53. PubMed ID: 30672869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The estimation of the probability of tumor malignacy on the basis of test combination in the primary diagnosis of adnexal tumors].
    Smoleń A; Stachowicz N; Czekierowski A; Kotarski J
    Ginekol Pol; 2010 Apr; 81(4):254-61. PubMed ID: 20476596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
    Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
    Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.